Protein Kinase Inhibitors: all 15,278 studies that test it
Page 108 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.
- Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract CancerWithdrawnNCT03129074Phase 2
- Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLLActive, not recruitingNCT03128879Phase 2
- Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast CancerTerminatedNCT03128619Phase 1
- A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care ExistedCompletedNCT03128164Phase 1
- AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR MutationsTerminatedNCT03127449Not applicable
- Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma PatientsCompletedNCT03127020Phase 2
- A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)Status unknownNCT03126799Phase 2
- A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)TerminatedNCT03125876Phase 1
- Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03125239Phase 1
- Histology-Independent Study of Palbociclib in Patients With Advanced CancerWithdrawnNCT03123744Phase 2
- Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerActive, not recruitingNCT03122717Phase 1/2
- Mesylate Apatinib for Stage Ⅳ STS After Failure of ChemotherapyStatus unknownNCT03121846Phase 2
- PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System LymphomaWithdrawnNCT03120000Phase 2
- Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid CancersCompletedNCT03118817Phase 1
- Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian CancerCompletedNCT03117933Phase 2
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaActive, not recruitingNCT03117751Phase 2/3
- A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing SpondylitisCompletedNCT03117270Phase 2
- Study of the AL3810 in the Treatment of Advanced Solid TumorCompletedNCT03117101Phase 1
- Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)TerminatedNCT03116971Phase 1
- Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJAStatus unknownNCT03116555Phase 2
- Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)Active, not recruitingNCT03114527Phase 2
- Dose Finding Study of TNO155 in Adult Patients With Advanced Solid TumorsTerminatedNCT03114319Phase 1
- CBP501, Cisplatin and Nivolumab in Advanced Refractory TumorsCompletedNCT03113188Phase 1
- CDK4/6 Inhibition in Locally Advanced/Metastatic ChordomaCompletedNCT03110744Phase 2
- Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective StudyStatus unknownNCT03110484Phase 2
- Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular CarcinomaCompletedNCT03109886Phase 2
- Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)WithdrawnNCT03109301Phase 2
- Evaluation of PHP-201 Ophthalmic Solution in Patients With Normal Tension GlaucomaCompletedNCT03106532Phase 2
- Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR AmplificationTerminatedNCT03106155Phase 2
- Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter TrialWithdrawnNCT03104335Phase 2
- Apatinib for the Elderly Advanced Gastric CancerCompletedNCT03104283Phase 2
- Novel Compositions for Treating or Preventing Dermal DisordersCompletedNCT03103893Phase 1/2
- A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic ArthritisCompletedNCT03101670Phase 2
- A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung CancerStatus unknownNCT03100955Phase 3
- A Phase I Study of TQ-B3139 on Tolerance and PharmacokineticsStatus unknownNCT03099330Phase 1
- Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular CarcinomaStatus unknownNCT03097848Not applicable
- A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated LiposarcomaStatus unknownNCT03096912Phase 2
- A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck CancersStatus unknownNCT03096184Phase 2
- A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)CompletedNCT03096080Phase 1
- A Phase I Trial of LY3143921 Hydrate in Solid TumoursCompletedNCT03096054Phase 1
- CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell CarcinomaStatus unknownNCT03095040Phase 3
- Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone LymphomaTerminatedNCT03093831Phase 2
- A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT03091257Phase 1
- Ribociclib and Bicalutamide in AR+ TNBCActive, not recruitingNCT03090165Phase 1/2
- Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced MelanomaStatus unknownNCT03088176Phase 1
- Biomarker-based Study in R/M SCCHNActive, not recruitingNCT03088059Phase 2
- Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124WithdrawnNCT03087968Early Phase 1
- Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT03087448Phase 1
- Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast CancerStatus unknownNCT03086785Phase 2
- Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard ChemotherapyCompletedNCT03086538Phase 2
- A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs HerceptinStatus unknownNCT03085368Phase 2/3
- Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid CancerActive, not recruitingNCT03085056Early Phase 1
- Afatinib in Locally Advanced and Metastatic ChordomaCompletedNCT03083678Phase 2
- Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line ChemotherapyTerminatedNCT03082833Phase 2
- A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) MutationsTerminatedNCT03082300Phase 1
- A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid TumoursCompletedNCT03082053Phase 1
- Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal CancerCompletedNCT03081494Phase 1
- Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast CancerWithdrawnNCT03081234Phase 3
- Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)Status unknownNCT03080805Phase 3
- Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid LeukemiaTerminatedNCT03079505Phase 3
- A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer PatientsCompletedNCT03075462Phase 1
- Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLCStatus unknownNCT03074864Phase 2/3
- Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's LymphomaTerminatedNCT03074825Phase 1
- Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDSCompletedNCT03074006Phase 1
- Phase 1 Study of the Effects of Combining Topical FDA-approved Drugs on Age-related Pathways on the Skin of Healthy VolunteersCompletedNCT03072485Phase 1
- Vistusertib (AZD2014) For Recurrent Grade II-III MeningiomasStatus unknownNCT03071874Phase 2
- A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ AdenocarcinomaStatus unknownNCT03071042Phase 1
- Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell TumorActive, not recruitingNCT03069469Phase 1/2
- A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With MyelofibrosisActive, not recruitingNCT03069326Phase 2
- A Study to Determine the Effect of Food on the Pharmacokinetics of Erdafitinib in Healthy ParticipantsCompletedNCT03066687Phase 1
- Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.CompletedNCT03066427Phase 2
- Poziotinib in EGFR Exon 20 Mutant Advanced NSCLCTerminatedNCT03066206Phase 2
- Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)CompletedNCT03065621Phase 2
- Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS MutationTerminatedNCT03065387Phase 1
- Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid TumorsSuspendedNCT03065062Phase 1
- Study of BCD-115 in Women With ER(+) HER2(-) Local Advanced and Metastatic Breast CancerCompletedNCT03065010Phase 1
- A Phase II Study of Apatinib in STS PatientsStatus unknownNCT03064243Phase 2
- A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)CompletedNCT03062943Phase 2
- Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line TherapyTerminatedNCT03061708Phase 2
- A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHLStatus unknownNCT03060850Phase 1
- Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)CompletedNCT03059797Phase 2
- Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular CarcinomaTerminatedNCT03059147Phase 1
- A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKIWithdrawnNCT03058094Phase 3
- Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid TumorsCompletedNCT03057145Phase 1
- Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian CancerCompletedNCT03056833Phase 1
- Metformin in Intrahepatic Cholestasis of PregnancyStatus unknownNCT03056274Phase 2/3
- First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845CompletedNCT03054402Phase 1
- Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT03054038Phase 1
- Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 TreatmentCompletedNCT03053219Phase 1
- Copanlisib and Gemcitabine in Relapsed/Refractory PTCLCompletedNCT03052933Phase 1/2
- First-in-Human Study of KO-947 in Non-Hematological MalignanciesTerminatedNCT03051035Phase 1
- Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung CancerStatus unknownNCT03050411Phase 1
- Bioequivalence Study of Gefitinib Tablets Under Fed ConditionsCompletedNCT03050177Phase 1
- Bioequivalence Study of Gefitinib Tablets Under Fasting ConditionsCompletedNCT03050164Phase 1
- Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid CancerStatus unknownNCT03048877Phase 3
- Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLCCompletedNCT03046992Phase 1/2
- Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)Status unknownNCT03046979Phase 2
- Effect of BMS-986165 on the Pharmacokinetics of RosuvastatinCompletedNCT03044873Phase 1
- Study of Regorafenib in Patients With Advanced Myeloid MalignanciesCompletedNCT03042689Phase 1
- A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 StudyWithdrawnNCT03042013Phase 2